Our inquiry about how HME suppresses STAT3 activation revealed that SRC appears as the primary STAT3 upstream kinase targeted by HME, as the levels of tyrosine 416-phosphorylated SRC were markedly lowered in all HME-treated bladder cancer cell lines (Figure 5). The gene discussed is STAT3; the disease is urinary bladder cancer.